ASCO 2020：11项中国深入研究入选口头报告，17项Poster报告

受亚洲地区新冠疫情制约，原定于5年末29日~6年末2日在芝加哥举行的美国针灸分析会（ASCO）年会今年将首次以线上基本承办，这是目前最大规模的线上嘉年华。从前，大会的概要题目公布，共103个sessions，之中国共有11项分析入选为口头报告，17项入选为Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

萘替尼或拉帕替尼加卡培他滨用做HER2+冠心病乳腺十二指肠癌（PHOEBE）：一项III期随机试制。

第二场：冠心病乳腺十二指肠癌

原作者：之兰州大学病房徐兵河系主任、马飞系主任，南京大学附属病房胡夕春系主任等

概要号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴性乳腺十二指肠癌标准疗程后卡培他滨确保节拍复发的III期试制（SYSUCC-001）。

第二场：乳腺十二指肠癌—连续性/区域/除此以外疗程

原作者：之东兴大学预防之外围三王树森系主任等

概要号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

并用冠心病脑的性状特质来计算脑脊液之中循环DNA检验的概率: 新辅助工具对付杨家取胜

第二场：新辅助工具解决杨家疑虑

原作者：赵美芹 赵菲尔德等

概要号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对比索拉非尼作为后半期肾脏蛋白质十二指肠癌的一线疗程：一项封闭标记、随机、多之外围II/III期试制。

第二场：消化道十二指肠癌—十二指肠胃、凋亡和肾脏胆

原作者：四川大学宝兴病房毕锋系主任、之中国祖国武装警察部队八一病房秦叔逵系主任等

概要号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

之中国后半期肾脏十二指肠癌病人阿帕替尼双线疗程：一项随机、安慰剂依此、CPAIII期分析

第二场：消化道十二指肠癌—十二指肠胃、凋亡和肾脏胆

原作者：之中国祖国武装警察部队八一病房秦叔逵系主任、四川大学宝兴病房赵秋系主任等

概要号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

后半期风湿热卵巢十二指肠癌二次蛋白质减灭术的一项随机III期试制：SOC1 / SGOG-OV2。

简介：妇科帕金森氏症

原作者：南京大学附属之东兴病房臧荣余系主任等

概要：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈十二指肠癌根治性子宫畸形后除此以外疗程之中的序贯放复发对比单独前列腺癌或该系统放复发（STARS分析）：一项随机、依此、封闭标记的III期试制。

大会：妇科帕金森氏症

原作者：之东兴大学预防之外围黄鹤系主任、刘继红系主任等

概要号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：除此以外吉非替尼对比复发用做可切除的EGFR突变的N1-N2期NSCLC-随机III期针灸试制的最终总体生存分析。

简介：肺十二指肠癌—非小蛋白质连续性-区域/小蛋白质/其他头部

原作者：广东省祖国病房吴一龙系主任等

概要号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR突变寡转移非小蛋白质肺十二指肠癌病人一线酪氨酸激酶衍生物联合行动或不联合行动积极前线连续性前列腺癌：III期封闭标记针灸随机试制（SINDAS）的之前期结果（NCT02893332）。

简介：肺十二指肠癌-非小蛋白质转移

原作者：南充祖国病房曾铭系主任等

概要：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对简而言之死亡-1（PD-1）的人源化IgG4制剂联合行动阿昔替尼用做冠心病黏膜黑色素肿病人的Ib期分析的总生存期和微生物标志物分析。

简介：黑色素肿/皮肤十二指肠癌

原作者：华东师范大学病房郭军、盛锡楠系主任等

概要：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的兼容性和结果：常用CAR-T蛋白质首次生理试制疗程中风/难治性T蛋白质急性淋巴蛋白质胃癌（r/r T-ALL）的兼容性和。大会：开发之中的疗程技术-免疫疗程。原作者：三王恰巧等概要：3013月历：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在后半期胃大块蛋白质十二指肠癌病人之中的应用：一项随机的封闭标记II期试制（ORIENT-2）。大会：消化道十二指肠癌-十二指肠胃十二指肠癌、凋亡十二指肠癌和肾脏胆道十二指肠癌原作者：徐建明系主任等概要：4511月历：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D免疫CAR-T蛋白质对髓母蛋白质肿的根除性疗程大会：之周围神经原作者：代红久、孙斌、杨东、徐晖、朱华以、魏佳、赵旭东概要：2522月历。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在后半期错配修复缺陷病人之中的应用大会：开发之中的疗程学-免疫疗程原作者：沈琳系主任等概要：3021月历。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 骨髓CD7-CART疗程中风/难治性ACUTE淋巴蛋白质胃癌/淋巴肿的尚未有生理针灸试制大会: 开发性疗程学-免疫疗程原作者简介：张明志，杨林等概要：3026月历: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 萨里替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度酮（T）联合行动应用做后半期实体肿病人的Ib期分析大会：发展性疗程学；还有分子靶向药物和微生物学原作者：龚继芳，沈琳系主任等概要：3523月历：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin联合行动抗癌药物和nedaplatin疗程风湿热或冠心病胃大块蛋白质十二指肠癌（ESCC）病人的II期分析。大会：消化道十二指肠癌-十二指肠胃、凋亡和肾脏胆道十二指肠癌的分析原作者：三王志极强，赵玉红，三王德申，三王凤华，任超，谭琼 三王志极强、赵玉红、三王德深、三王凤华、任超、谭琼概要：4522月历：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.大会：消化道十二指肠癌-十二指肠胃十二指肠癌、凋亡十二指肠癌和肾脏胆管十二指肠癌的双线疗程原作者：宋艳等概要：4524月历：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种血液外体的环RNA决策树用做初始活检时检验高等级十二指肠癌的血液外体的环RNA决策树：一项多之外围的回顾性分析大会：泌尿生殖系统帕金森氏症；还有-十二指肠癌、睾丸十二指肠癌和十二指肠癌原作者简介：Liaoyuan Li等概要：5522月历。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 连续性后半期宫颈十二指肠癌并发复发后的除此以外复发大会: 妇科帕金森氏症原作者简介： 赵珉珉等概要：6031月历：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼疗程甲状腺髓性十二指肠癌的相关性：基于ALTER01031试制的分析。会话：多毛原作者：天津市病房用心系主任概要：6526月历。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年龄对安洛替尼疗程后病人结局的制约: ALTER01031的亚组分析大会：多毛原作者：天津市病房用心系主任概要：6527月历。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA分析计算I-IIIA期非小蛋白质肺十二指肠癌（NSCLC）病人术后中风: GASTO1035和GASTO1018的结果大会：肺十二指肠癌-非小蛋白质连续性-邻近地区/小蛋白质/小蛋白质/其他胸科帕金森氏症原作者：Si-Yu Wang等概要：9023月历：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小蛋白质肺十二指肠癌（NSCLC）之中EGFR酪氨酸激酶衍生物的新型病毒性组态大会:肺十二指肠癌-非小蛋白质冠心病肺十二指肠癌原作者简介：赵昕，金恰巧，满宇，欧秋香，双带，薛武，杨少，范敏 赵昕、金恰巧、满宇、欧秋香、双带、薛武、杨绍、范敏概要：9528月历：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1试制之中后半期黑色素肿总生存的替代终点大会：黑色素肿/皮肤十二指肠癌原作者：聂润聪，袁书极强，赵元芳，陈英波，周志伟 聂润聪、袁书极强、赵元芳、陈英波、周志伟概要：10030月历：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼疗程中风或冠心病原发性恶性骨病人的II期分析大会： 病症原作者：唐丽娜，牛晓辉，三黄克诚，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、三汪直、蔡启庆、涂崇奇、范正福、杨瑶概要：11525月历。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 近期评价安罗替尼在后半期病症病人多线疗程之中的兼容性和。大会：病症原作者：姚伟涛，的三王室极强，张鹏，三王欣，杜新辉，田志浩，牛晓颖 姚伟涛、的三王室极强、张鹏、三王鑫、杜鑫辉、田志超、牛晓英概要：11526月历：414